Recently, PET-based detection and monitoring of metastasis cancer has utilized the following antibodies: 111In-labeled anti-CDH17 (gastric cancer) [114], 177Lu-labeled anti-CD55 (lung cancer) [115], and radio-labeled anti-ERBB2 (various labeling, including 89Zr, 64Cu, 111In) (breast cancer) [116]. Here, ERBB2 is linked to breast carcinoma.